ondansetron has been researched along with Obsessive-Compulsive Disorder in 15 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " granisetron in patients with treatment-resistant obsessive-compulsive disorder." | 9.30 | Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. ( Abdolrazaghnejad, A; Aghakarim Alamdar, M; Ebrahimi-Monfared, M; Massoudifar, A; Mohammadbeigi, A; Saber, R; Sharafkhah, M, 2019) |
| "The aim of this study was to evaluate low-dose ondansetron as an augmentation strategy in patients with obsessive-compulsive disorder (OCD) who do not adequately respond to serotonin reuptake inhibits (SRIs)." | 9.19 | Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2014) |
| "The aim of this study was to investigate the efficacy and safety of ondansetron as an augmentative agent to fluvoxamine in the treatment of patients with obsessive-compulsive disorder (OCD)." | 9.19 | Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. ( Akhondzadeh, S; Fallah, J; Heidari, M; Hosseini, SM; Maleki, H; Tabrizi, M; Taghvaei, R; Zarei, M, 2014) |
| "To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD)." | 9.14 | A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. ( Feizy, F; Malayeri, A; Motlagh, I; Sayyah, M; Siahpoosh, A; Soltani, F, 2010) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 7.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| " The drug was initiated at a dosage of 0." | 6.74 | Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2009) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 6.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| "Ondansetron is an experimental alternative for such patients." | 5.42 | Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. ( Andrade, C, 2015) |
| " granisetron in patients with treatment-resistant obsessive-compulsive disorder." | 5.30 | Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. ( Abdolrazaghnejad, A; Aghakarim Alamdar, M; Ebrahimi-Monfared, M; Massoudifar, A; Mohammadbeigi, A; Saber, R; Sharafkhah, M, 2019) |
| "The aim of this study was to evaluate low-dose ondansetron as an augmentation strategy in patients with obsessive-compulsive disorder (OCD) who do not adequately respond to serotonin reuptake inhibits (SRIs)." | 5.19 | Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2014) |
| "The aim of this study was to investigate the efficacy and safety of ondansetron as an augmentative agent to fluvoxamine in the treatment of patients with obsessive-compulsive disorder (OCD)." | 5.19 | Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. ( Akhondzadeh, S; Fallah, J; Heidari, M; Hosseini, SM; Maleki, H; Tabrizi, M; Taghvaei, R; Zarei, M, 2014) |
| "To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD)." | 5.14 | A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. ( Feizy, F; Malayeri, A; Motlagh, I; Sayyah, M; Siahpoosh, A; Soltani, F, 2010) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 3.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "Memantine was found to be most effective augmentation agent for SRIs in OCD, followed by lamotrigine, ondansetron and granisetron with moderate certainty of evidence." | 3.01 | Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis. ( Maiti, R; Mishra, A; Mishra, BR; Srinivasan, A, 2023) |
| " The drug was initiated at a dosage of 0." | 2.74 | Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. ( Antonini, S; Bernardi, S; Hollander, E; Pallanti, S; Singh, N, 2009) |
| "Pretreatment with ondansetron did not affect any of the self-rated behavioral symptoms." | 2.69 | Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. ( Broocks, A; Canter, S; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1998) |
| "Ondansetron treatment was associated with a significant decrease in the severity of tics." | 2.69 | Ondansetron treatment in patients with Tourette's syndrome. ( Cohen, DJ; Laor, N; Toren, P; Weizman, A; Wolmer, L, 1999) |
| "Ondansetron is an experimental alternative for such patients." | 1.42 | Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. ( Andrade, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suhas, S | 1 |
| Malo, PK | 1 |
| Kumar, V | 1 |
| Issac, TG | 1 |
| Chithra, NK | 1 |
| Bhaskarapillai, B | 1 |
| Reddy, YCJ | 2 |
| Rao, NP | 1 |
| Maiti, R | 1 |
| Mishra, A | 1 |
| Srinivasan, A | 1 |
| Mishra, BR | 1 |
| Yadav, S | 1 |
| Takács, A | 1 |
| Pantelis, C | 1 |
| Thomas, N | 1 |
| Kalyani, BG | 1 |
| Hegde, A | 1 |
| Arumugham, SS | 1 |
| Narayanaswamy, JC | 1 |
| Math, SB | 1 |
| M Koran, L | 1 |
| Aboujaoude, E | 1 |
| Sharafkhah, M | 1 |
| Aghakarim Alamdar, M | 1 |
| Massoudifar, A | 1 |
| Abdolrazaghnejad, A | 1 |
| Ebrahimi-Monfared, M | 1 |
| Saber, R | 1 |
| Mohammadbeigi, A | 1 |
| Pallanti, S | 2 |
| Bernardi, S | 2 |
| Antonini, S | 2 |
| Singh, N | 2 |
| Hollander, E | 2 |
| Heidari, M | 1 |
| Zarei, M | 1 |
| Hosseini, SM | 1 |
| Taghvaei, R | 1 |
| Maleki, H | 1 |
| Tabrizi, M | 1 |
| Fallah, J | 1 |
| Akhondzadeh, S | 1 |
| Andrade, C | 1 |
| Soltani, F | 1 |
| Sayyah, M | 1 |
| Feizy, F | 1 |
| Malayeri, A | 1 |
| Siahpoosh, A | 1 |
| Motlagh, I | 1 |
| Hewlett, WA | 1 |
| Schmid, SP | 1 |
| Salomon, RM | 1 |
| Rizzo, R | 1 |
| Marino, S | 1 |
| Gulisano, M | 1 |
| Robertson, MM | 1 |
| Broocks, A | 1 |
| Pigott, TA | 1 |
| Hill, JL | 1 |
| Canter, S | 1 |
| Grady, TA | 1 |
| L'Heureux, F | 1 |
| Murphy, DL | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Cohen, DJ | 1 |
| Wolmer, L | 1 |
| Weizman, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study[NCT00796497] | Phase 4 | 14 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ondansetron and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials.
Topics: Adult; Aripiprazole; Child; Chronic Disease; Humans; Network Meta-Analysis; Obsessive-Compulsive Dis | 2023 |
Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Topics: Bayes Theorem; Drug Therapy, Combination; Granisetron; Humans; Lamotrigine; Memantine; Network Meta- | 2023 |
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
Topics: Caffeine; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Ketamine; Memantine; Obse | 2018 |
8 trials available for ondansetron and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.
Topics: Double-Blind Method; Granisetron; Obsessive-Compulsive Disorder; Ondansetron; Serotonin Antagonists | 2019 |
Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
Topics: Adult; Aged; Anti-Anxiety Agents; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; M | 2014 |
Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Male | 2014 |
Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Topics: Adolescent; Adult; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Female; Humans; | 2009 |
A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Interview, Psycho | 2010 |
Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Ob | 2003 |
Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Topics: Adult; Analysis of Variance; Behavioral Symptoms; Double-Blind Method; Drug Interactions; Female; Hu | 1998 |
Ondansetron treatment in patients with Tourette's syndrome.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Ondansetron; Pi | 1999 |
4 other studies available for ondansetron and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Ondansetron augmentation for the management of obsessive-compulsive disorder in a patient with treatment-resistant schizophrenia.
Topics: Humans; Obsessive-Compulsive Disorder; Ondansetron; Schizophrenia; Selective Serotonin Reuptake Inhi | 2021 |
Is Ondansetron Augmentation Effective in Obsessive-Compulsive Disorder?
Topics: Drug Therapy, Combination; Humans; Obsessive-Compulsive Disorder; Ondansetron; Outcome Assessment, H | 2017 |
Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder.
Topics: Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Humans; Obsessive-Compulsive Di | 2015 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |